Knight Therapeutics Inc. (KHTRF)

4.2600 +0.0700 (+1.67%) At close: 12:06PM EDT

Knight Therapeutics Inc.

3400 de Maisonneuve Boulevard West
Suite 1055
Montreal, QC H3Z 3B8
Canada
514-484-4483
https://www.gud-knight.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 725

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.	Executive Chairman	182.84k	N/A	1969
Ms. Samira Sakhia BCom, CA, CPA, MBA	President, CEO & Director	491.31k	N/A	1968
Mr. Arvind Utchanah	Chief Financial Officer	442.44k	N/A	N/A
Ms. Amal Khouri B.Sc., M.B.A.	Chief Business Officer	378.8k	N/A	N/A
Mr. Jeff Martens	Global Vice President of Commercial	306.32k	N/A	N/A
Mr. Stephani Saverio	Vice President of Business Development	321.07k	N/A	N/A
Mr. Leopoldo Bosano	Vice-President of Manufacturing & Operations	N/A	N/A	N/A
Ms. Monica Percario	Global Vice President of Scientific Affairs	N/A	N/A	N/A
Mr. Henrique Dias	Global Director of Marketing	N/A	N/A	N/A
Ms. Susan Caroline Emblem	Global Vice President of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Corporate governance

Knight Therapeutics Inc.’s ISS governance QualityScore as of 1 May 2024 is 5. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.